Colorectal cancer 3

Common Name(s)

Colorectal cancer 3

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Colorectal cancer 3" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Colorectal cancer 3" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Colorectal cancer 3" returned 209 free, full-text research articles on human participants. First 3 results:

First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials.
 

Author(s): Harpreet S Wasan, Peter Gibbs, Navesh K Sharma, Julien Taieb, Volker Heinemann, Jens Ricke, Marc Peeters, Michael Findlay, Andrew Weaver, Jamie Mills, Charles Wilson, Richard Adams, Anne Francis, Joanna Moschandreas, Pradeep S Virdee, Peter Dutton, Sharon Love, Val Gebski, Alastair Gray, , , , Guy van Hazel, Ricky A Sharma

Journal: Lancet Oncol.. 2017 Sep;18(9):1159-1171.

 

Data suggest selective internal radiotherapy (SIRT) in third-line or subsequent therapy for metastatic colorectal cancer has clinical benefit in patients with colorectal liver metastases with liver-dominant disease after chemotherapy. The FOXFIRE, SIRFLOX, and FOXFIRE-Global randomised ...

Last Updated: 31 Dec 1969

Go To URL
(-)-Epigallocatechin-3-Gallate Inhibits Colorectal Cancer Stem Cells by Suppressing Wnt/β-Catenin Pathway.
 

Author(s): Yue Chen, Xiao-Qian Wang, Qi Zhang, Jian-Yun Zhu, Yuan Li, Chun-Feng Xie, Xiao-Ting Li, Jie-Shu Wu, Shan-Shan Geng, Cai-Yun Zhong, Hong-Yu Han

Journal:

 

The beneficial effects of tea consumption on cancer prevention have been generally reported, while (-)-Epigallocatechin-3-gallate (EGCG) is the major active component from green tea. Cancer stem cells (CSCs) play a crucial role in the process of cancer development. Targeting CSCs ...

Last Updated: 31 Dec 1969

Go To URL
Prosurvival long noncoding RNA regulates a subset of p53 targets in human colorectal cancer cells by binding to Matrin 3.
 

Author(s): Ritu Chaudhary, Berkley Gryder, Wendy S Woods, Murugan Subramanian, Matthew F Jones, Xiao Ling Li, Lisa M Jenkins, Svetlana A Shabalina, Min Mo, Mary Dasso, Yuan Yang, Lalage M Wakefield, Yuelin Zhu, Susan M Frier, Branden S Moriarity, Kannanganattu V Prasanth, Pablo Perez-Pinera, Ashish Lal

Journal:

 

Thousands of long noncoding RNAs (lncRNAs) have been discovered, yet the function of the vast majority remains unclear. Here, we show that a p53-regulated lncRNA which we named (p53-induced noncoding RNA), is induced ~100-fold after DNA damage and exerts a prosurvival function in ...

Last Updated: 31 Dec 1969

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Colorectal cancer 3" returned 4 free, full-text review articles on human participants. First 3 results:

Focal Adhesion Kinase-Dependent Role of the Soluble Form of Neurotensin Receptor-3/Sortilin in Colorectal Cancer Cell Dissociation.
 

Author(s): Sophie Béraud-Dufour, Chistelle Devader, Fabienne Massa, Morgane Roulot, Thierry Coppola, Jean Mazella

Journal:

 

The aim of the present review is to unravel the mechanisms of action of the soluble form of the neurotensin (NT) receptor-3 (NTSR3), also called Sortilin, in numerous physiopathological processes including cancer development, cardiovascular diseases and depression. Sortilin/NTSR3 ...

Last Updated: 31 Dec 1969

Go To URL
New strategies in colorectal cancer: biomarkers of response to epidermal growth factor receptor monoclonal antibodies and potential therapeutic targets in phosphoinositide 3-kinase and mitogen-activated protein kinase pathways.
 

Author(s): Arvind Dasari, Wells A Messersmith

Journal: Clin. Cancer Res.. 2010 Aug;16(15):3811-8.

 

Initial experience with the epidermal growth factor receptor monoclonal antibodies (EGFR MoAb) in unselected patients with metastatic colorectal cancer (mCRC) showed that most of the treated patients did not derive therapeutic benefit. This outcome has driven the search for biomarkers ...

Last Updated: 31 Dec 1969

Go To URL
Development of quality indicators for colorectal cancer surgery, using a 3-step modified Delphi approach.
 

Author(s): Anna R Gagliardi, Marko Simunovic, Bernard Langer, Hartley Stern, Adalsteinn D Brown

Journal: Can J Surg. 2005 Dec;48(6):441-52.

 

Little performance measurement has been undertaken in the area of oncology, particularly for surgery, which is a pivotal event in the continuum of cancer care. This work was conducted to develop indicators of quality for colorectal cancer surgery, using a 3-step modified Delphi approach.

Last Updated: 31 Dec 1969

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Study on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation Stage III or II High Risk
 

Status: Not yet recruiting

Condition Summary: Colorectal Cancer

 

Last Updated: 24 Oct 2016

Go to URL

Last Updated: 13 Mar 2018

Go to URL
CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer
 

Status: Recruiting

Condition Summary: Colorectal Cancer; Colon Cancer; Rectal Cancer; Solid Tumor

 

Last Updated: 20 Mar 2018

Go to URL